The Division Bench dismissed the connected writ appeals, while making a limited modification to the Single Judge’s findings concerning the Bar Council of Kerala. In light of…
Helex raises $3.5 mn to develop targeted medicines for genetic kidney diseases
Update / Judgement Date
30 Oct 2025
Source
Author
Team — WCP Legal Desk
Reading Time
1 min read
View Count
1
Biotech startup Helex secured $3.5 million to develop targeted therapies for rare genetic kidney diseases. The article explains how Helex’s approach uses genetic research and precision medicine to address underserved medical conditions. The funding will aid R&D, clinical trials, and regulatory clearances. The piece also touches upon investor interest in biotech innovation amid evolving health-tech regulations.